The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives BPC 157: Miracle Healing Peptide or Hidden Danger? FDA releases denial letters for unapproved drugs, a step toward transparency